Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency

H. Farkas, Dorottya Csuka, Nóra Veszeli, Zsuzsanna Zotter, Erika Szabó, L. Varga

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Conestat alfa, a recombinant human C1 inhibitor (rhC1-INH) is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-INH (HAE-C1-INH) deficiency. Our aim was to investigate the efficacy and safety profile of conestat alfa in patients with HAE-C1-INH, under real-life conditions. We analyzed 65 edematous episodes requiring acute treatment and occurring in two female HAE-C1- COPY INH patients. The patients were treated at home with rhC1-INH per occasion. They recorded the time of rhC1-INH administration, the time to the onset of improvement, and time to the complete resolution of symptoms, as well as the side effects. Symptom severity and patient satisfaction were measured with a visual analog scale (VAS). Thirty-three HAE attacks occurred in submucosal tissue, 17 in subcutaneous tissue, and 15 had mixed locations. After the administration of rhC1-INH, clinical symptoms improved within 0.50 (0.17- 4.50 hours) hours and resolved completely within 9.00 (1.67-58.75 hours) hours. The time between the onset of the attack and the administration of rhC1-INH was correlated with the time when the symptoms stopped worsening (R = 0.3212; p = 0.0096) and the time to complete resolution of the symptoms (R = 0.4774; p <0.0001). The time to response to the drug differed with attack location. The efficacy and safety of rhC1-INH persisted after repeated use. None of the patients experienced a recurrence of the HAE attack or drug-related systemic adverse events. The mean VAS score of patient satisfaction was 93.14. Home treatment with rhC1-INH was an effective and well-tolerated therapy for all types of HAE attacks.

Original languageEnglish
Pages (from-to)255-259
Number of pages5
JournalAllergy and Asthma Proceedings
Volume35
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Hereditary Angioedemas
Visual Analog Scale
Patient Satisfaction
Therapeutics
Safety
Subcutaneous Tissue
human SERPING1 protein
conestat alpha
Pharmaceutical Preparations
Recurrence

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. / Farkas, H.; Csuka, Dorottya; Veszeli, Nóra; Zotter, Zsuzsanna; Szabó, Erika; Varga, L.

In: Allergy and Asthma Proceedings, Vol. 35, No. 3, 2014, p. 255-259.

Research output: Contribution to journalArticle

Farkas, H. ; Csuka, Dorottya ; Veszeli, Nóra ; Zotter, Zsuzsanna ; Szabó, Erika ; Varga, L. / Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. In: Allergy and Asthma Proceedings. 2014 ; Vol. 35, No. 3. pp. 255-259.
@article{43c18e6ec5a64e5ab7c62e3461f7186a,
title = "Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency",
abstract = "Conestat alfa, a recombinant human C1 inhibitor (rhC1-INH) is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-INH (HAE-C1-INH) deficiency. Our aim was to investigate the efficacy and safety profile of conestat alfa in patients with HAE-C1-INH, under real-life conditions. We analyzed 65 edematous episodes requiring acute treatment and occurring in two female HAE-C1- COPY INH patients. The patients were treated at home with rhC1-INH per occasion. They recorded the time of rhC1-INH administration, the time to the onset of improvement, and time to the complete resolution of symptoms, as well as the side effects. Symptom severity and patient satisfaction were measured with a visual analog scale (VAS). Thirty-three HAE attacks occurred in submucosal tissue, 17 in subcutaneous tissue, and 15 had mixed locations. After the administration of rhC1-INH, clinical symptoms improved within 0.50 (0.17- 4.50 hours) hours and resolved completely within 9.00 (1.67-58.75 hours) hours. The time between the onset of the attack and the administration of rhC1-INH was correlated with the time when the symptoms stopped worsening (R = 0.3212; p = 0.0096) and the time to complete resolution of the symptoms (R = 0.4774; p <0.0001). The time to response to the drug differed with attack location. The efficacy and safety of rhC1-INH persisted after repeated use. None of the patients experienced a recurrence of the HAE attack or drug-related systemic adverse events. The mean VAS score of patient satisfaction was 93.14. Home treatment with rhC1-INH was an effective and well-tolerated therapy for all types of HAE attacks.",
author = "H. Farkas and Dorottya Csuka and N{\'o}ra Veszeli and Zsuzsanna Zotter and Erika Szab{\'o} and L. Varga",
year = "2014",
doi = "10.2500/aap.2014.35.3743",
language = "English",
volume = "35",
pages = "255--259",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency

AU - Farkas, H.

AU - Csuka, Dorottya

AU - Veszeli, Nóra

AU - Zotter, Zsuzsanna

AU - Szabó, Erika

AU - Varga, L.

PY - 2014

Y1 - 2014

N2 - Conestat alfa, a recombinant human C1 inhibitor (rhC1-INH) is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-INH (HAE-C1-INH) deficiency. Our aim was to investigate the efficacy and safety profile of conestat alfa in patients with HAE-C1-INH, under real-life conditions. We analyzed 65 edematous episodes requiring acute treatment and occurring in two female HAE-C1- COPY INH patients. The patients were treated at home with rhC1-INH per occasion. They recorded the time of rhC1-INH administration, the time to the onset of improvement, and time to the complete resolution of symptoms, as well as the side effects. Symptom severity and patient satisfaction were measured with a visual analog scale (VAS). Thirty-three HAE attacks occurred in submucosal tissue, 17 in subcutaneous tissue, and 15 had mixed locations. After the administration of rhC1-INH, clinical symptoms improved within 0.50 (0.17- 4.50 hours) hours and resolved completely within 9.00 (1.67-58.75 hours) hours. The time between the onset of the attack and the administration of rhC1-INH was correlated with the time when the symptoms stopped worsening (R = 0.3212; p = 0.0096) and the time to complete resolution of the symptoms (R = 0.4774; p <0.0001). The time to response to the drug differed with attack location. The efficacy and safety of rhC1-INH persisted after repeated use. None of the patients experienced a recurrence of the HAE attack or drug-related systemic adverse events. The mean VAS score of patient satisfaction was 93.14. Home treatment with rhC1-INH was an effective and well-tolerated therapy for all types of HAE attacks.

AB - Conestat alfa, a recombinant human C1 inhibitor (rhC1-INH) is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-INH (HAE-C1-INH) deficiency. Our aim was to investigate the efficacy and safety profile of conestat alfa in patients with HAE-C1-INH, under real-life conditions. We analyzed 65 edematous episodes requiring acute treatment and occurring in two female HAE-C1- COPY INH patients. The patients were treated at home with rhC1-INH per occasion. They recorded the time of rhC1-INH administration, the time to the onset of improvement, and time to the complete resolution of symptoms, as well as the side effects. Symptom severity and patient satisfaction were measured with a visual analog scale (VAS). Thirty-three HAE attacks occurred in submucosal tissue, 17 in subcutaneous tissue, and 15 had mixed locations. After the administration of rhC1-INH, clinical symptoms improved within 0.50 (0.17- 4.50 hours) hours and resolved completely within 9.00 (1.67-58.75 hours) hours. The time between the onset of the attack and the administration of rhC1-INH was correlated with the time when the symptoms stopped worsening (R = 0.3212; p = 0.0096) and the time to complete resolution of the symptoms (R = 0.4774; p <0.0001). The time to response to the drug differed with attack location. The efficacy and safety of rhC1-INH persisted after repeated use. None of the patients experienced a recurrence of the HAE attack or drug-related systemic adverse events. The mean VAS score of patient satisfaction was 93.14. Home treatment with rhC1-INH was an effective and well-tolerated therapy for all types of HAE attacks.

UR - http://www.scopus.com/inward/record.url?scp=84899812082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899812082&partnerID=8YFLogxK

U2 - 10.2500/aap.2014.35.3743

DO - 10.2500/aap.2014.35.3743

M3 - Article

C2 - 24801469

AN - SCOPUS:84899812082

VL - 35

SP - 255

EP - 259

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 3

ER -